Download presentation
Presentation is loading. Please wait.
Published byGregory Abraham Strickland Modified over 6 years ago
1
Increased atherosclerotic lesion area in apoE deficient mice overexpressing bovine growth hormone
Irene J. Andersson, Anna Ljungberg, Lennart Svensson, Li-Ming Gan, Jan Oscarsson, Göran Bergström Atherosclerosis Volume 188, Issue 2, Pages (October 2006) DOI: /j.atherosclerosis Copyright © 2005 Elsevier Ireland Ltd Terms and Conditions
2
Fig. 1 Systolic blood pressure (SBP) in male apoE−/−/bGH and apoE−/− littermate mice fed standard diet (A, n=10 apoE−/−/bGH, n=14 apoE−/−) or Western diet (B, n=6 apoE−/−/bGH, n=8 apoE−/−). Systolic blood pressure was measured using a non-invasive tail-cuff system. Values are means±S.E.M. *P<0.05, **P<0.01, Student's t-test. Atherosclerosis , DOI: ( /j.atherosclerosis ) Copyright © 2005 Elsevier Ireland Ltd Terms and Conditions
3
Fig. 2 Lesion area in the thoracic aorta (A, C) and the arch (B, D) of male apoE−/−/bGH and apoE−/− littermate mice fed standard diet (A, B) or Western diet (C, D). Lesion areas were quantified after staining with Sudan IV and are expressed as percentage of intimal area. **P<0.01, Mann–Whitney U-test. Atherosclerosis , DOI: ( /j.atherosclerosis ) Copyright © 2005 Elsevier Ireland Ltd Terms and Conditions
4
Fig. 3 Aortic sinus lesion area expressed as mm2 (A, C) and percentage (B, D) of total vessel cross-sectional area in male apoE−/−/bGH and apoE−/− littermate mice fed standard diet (A, B) or Western diet (C, D). Cross-sections from the aortic sinus were stained with the modified Russel–Movat pentachrome staining followed by quantification of lesion area. ***P<0.001, Mann–Whitney U-test. Atherosclerosis , DOI: ( /j.atherosclerosis ) Copyright © 2005 Elsevier Ireland Ltd Terms and Conditions
5
Fig. 4 Representative aortic sinus lesions in male apoE−/−/bGH (C, D) and apoE−/− littermate mice (A, B) fed standard diet. The aortic sinus cross-section is shown in (A) and (C) (10×, scale bar=300μm). Lesions in apoE−/− littermates ranged from regular fatty streaks to moderate plaques, whereas lesions in apoE−/−/bGH mice almost exclusively were moderate or severe plaques. The lesions shown in (B) and (D) (40×, scale bar=100μm) are classified as mild and severe alterations, respectively. Atherosclerosis , DOI: ( /j.atherosclerosis ) Copyright © 2005 Elsevier Ireland Ltd Terms and Conditions
6
Fig. 5 Total cholesterol, HDL cholesterol, and VLDL+LDL cholesterol in male apoE−/−/bGH and apoE−/− littermate mice fed standard diet (A, n=8 apoE−/−/bGH, n=7 apoE−/−) or Western diet (B, n=6 apoE−/−/bGH, n=8 apoE−/−). The cholesterol profiles were measured using a high performance liquid chromatography system. Values are means±S.E.M. *P<0.05, **P<0.01, ***P<0.001, Student's t-test. Atherosclerosis , DOI: ( /j.atherosclerosis ) Copyright © 2005 Elsevier Ireland Ltd Terms and Conditions
7
Fig. 6 Serum triglycerides (A, C) and apoB (B, D) in male apoE−/−/bGH and apoE−/− littermate mice fed standard diet (A, n=8 apoE−/−/bGH, n=11 apoE−/−; B, n=7 apoE−/−/bGH, n=11 apoE−/−) or Western diet (C, n=6 apoE−/−/bGH, n=8 apoE−/−; D, n=6 apoE−/−/bGH, n=8 apoE−/−). Serum triglyceride and apoB concentrations were determined with an enzymatic colorimetric assay and an electroimmunoassay, respectively. Values are means±S.E.M. **P<0.01, Student's t-test. Atherosclerosis , DOI: ( /j.atherosclerosis ) Copyright © 2005 Elsevier Ireland Ltd Terms and Conditions
8
Fig. 7 S-amyloid A in male apoE−/−/bGH and apoE−/− littermate mice fed standard diet (A, n=7 apoE−/−/bGH, n=5 apoE−/−) or Western diet (B, n=4 apoE−/−/bGH, n=6 apoE−/−) and hepatic CRP mRNA in apoE−/−/bGH and apoE−/− littermate mice fed Western diet (C, n=6 apoE−/−/bGH, n=8 apoE−/−). S-amyloid A was measured by a solid phase sandwich ELISA and hepatic CRP mRNA expression was determined with quantitative real-time PCR and normalized to the endogenous control 36B4. Values are means±S.E.M. **P<0.01, Student's t-test. Atherosclerosis , DOI: ( /j.atherosclerosis ) Copyright © 2005 Elsevier Ireland Ltd Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.